Terbaru

  • Bitcoin S (BTCS)

    The Bitcoin S (BTCS) transactionchain will integrate the value of public chain to build a global value transfer network. The CBNData data report shows that among the 120 annual consumer buzzwords in the five years from 2016 to 2020, blockchain ranks among the top. Recently, the BTCS transactionchain wallet has attracted the attention of many capital and media in the circle with its fast, safe tran
  • BYD Wins the Largest Pure-Electric Bus Order outside of China

    Bogotá, Colombia - BYD is proud to announce that it has exclusively won cumulative orders to supply 1,002-unit pure-electric buses to the capital of Colombia, Bogotá. This tender was open to all bus technologies, yet BYD won the trust and cooperation of its partners in the fiercely competitive bidding process thanks to its cutting-edge technologies, products and services. This is the largest order
  • Dab the 5G Era with the Perfume of Books and Fragrance of Ink — allow full rein to a better life with Hisense A7

    On Dec 22nd, Hisense’s new reading flagship cellphone A7 series was officially launched. This series is the continuation of the characteristics of Hisense A series' most typical ink screen design, namely e-ink screen, a kind of screen that uses electronic ink, which is also known as e-paper displays. This is the world's first 5G cellphone equipped with an ink screen, marking the official arrival o
  • BYD Delivers Largest Pure Electric Bus Fleet in Colombia

    Bogota, Colombia - On December 17, BYD announced the delivery of 470 pure electric buses to Bogota, the capital of Colombia. This is the country’s largest pure electric bus fleet, and also the largest bus fleet BYD has delivered in the Americas, which will effectively promote the already fast-growing electrified public transport systems in Colombia, Latin America and the entire Americas.
  • THE 9 th RESIDENCE | NEWERA DESIGN

    THE 9 th RESIDENCE "Break the cocoon and become a butterfly"Full record
  • Great News: a Special Drug from China for the treatment of novel coronavirus

    Duan Zhitang (Beijing) International Pharmaceutical Technology Development Co., Ltd. was founded in June 2009, the company has been committed to the inheritance and promotion of traditional Chinese medicine culture, focusing on the development and application of court secret recipe antiviral products, we have achieved a number of scientific and technological achievements in the field of antivirus,
  • Kewangan terdesentralisasi menambah ahli baru: sistem pengurusan kewangan P2P yang pertama diedarkan di dunia sangat dalam talian

    Desentralisasi adalah teknologi konsensus yang sangat baik untuk manusia, DeFi adalah aplikasi blockchain yang paling hebat, dan badan konsensus super siput adalah yang paling banyak Platform kewangan terdesentralisasi yang hebat. Ia menyediakan sistem pengurusan kewangan P2P yang diedarkan dengan mudah dan selamat untuk pengguna global. Ia dikembangkan secara bebas oleh pemain blockchain. Ia bena
  • The 2020 OCS to take new forms through upgrading

    The 2020 Convention on Exchange of Overseas Talents and the 22nd Guangzhou Convention of Overseas Chinese Scholars in Science and Technology (hereinafter referred to as the 2020 OCS) will be held from December 18 to 19 in Guangzhou, co-hosted by the Ministry of Education, Western Returned Scholars Association and Guangzhou Municipal Government and coordinated jointly by 29 cities including Beijing
  • Bityard exchange has obtained crypto financial licenses issued by multiple authorities

    Abstract: Bityard has obtained two crypto financial licenses issued by the Estonia Financial Supervision Authority (MTR), and will keep focusing on providing safe and reliable crypto trading services to the investors around the world.
  • Perdagangan salinan Bityard menjadikan perdagangan kontrak kripto lebih mudah

    Baru-baru ini, harga Bitcoin, salah satu daripada mata wang kripto arus utama di pasaran, mencapai $19,000. Pada masa yang sama, harga Ethereum juga melepasi $600 minggu lepas. Walaupun harga kebanyakan mata wang kripto telah menurun sedikit semenjak kebelakangan ini, pasaran masih sesak dengan peniaga dan pelabur.

Pautan mesra

Bayer and OrigiMed reached a partnership on CDx-IVD development

07-29     OrigiMed


• Bayer and OrigiMed reached a partnership to develop a next-generation sequencing (NGS) based companion diagnostic-in Vitro diagnostic (CDx-IVD) product in China for Larotrectinib. NTRK gene fusion detection

• The collaboration will begin with the development of a CDx-IVD for larotrectinib for the Chinese market. Larotrectinib is the world’s first TRK inhibitor to be approved in patients with TRK gene fusion cancer in all solid tumors in the United States (2018) and Europe (2019)

• The collaboration aims to develop a kit for China that helps to identify all TRK fusion cancer patients who may benefit from therapy.



Beijing, Shanghai, April 30th, 2020 - Bayer and OrigiMed (Shanghai) Co., Ltd. (referred to as "OrigiMed") today announced a strategic collaboration for the development and commercialization of NGS-based companion diagnostics – in vitro diagnostic (CDx-IVD) in China for detection of NTRK gene fusions. This collaboration will focus on developing a CDx-IVD for larotrectinib (Vitrakvi®) for the Chinese market, the first TRK inhibitor approved in the US (2018) and Europe (2019) for adult and pediatrics with TRK fusion cancer and is currently developed globally, including in China.


"Approved in various markets already including the US and EU, larotrectinib is a first-of-its-kind treatment exclusively designed for adults and children with TRK fusion cancer. It is also the first compound that received it's initial approved based on the molecular alteration (NTRK gene fusion) driving their cancer irrespective of the tumor site of origin," said Dr. Emmanuelle di Tomaso, Head of Oncology Precision Medicine, Bayer's Oncology Strategic Business Unit, "Cancer care is currently undergoing a paradigm shift, and as this new era of precision oncology treatment unfolds, we are continuing our effort of delivering innovative medicines such as larotrectinib, which can provide value to patients and their treating physicians around the world."  


"As one of the first NGS companies to introduce NTRK gene fusion detection in China, we are looking forward to working with Bayer to develop larotrectinib CDx-IVD, jointly support clinical trials of larotrectinib in mainland China and provide therapeutic benefits for more patients." The genomic testing and analysis of cancer patients to determine whether they are suitable for the treatment of larotrectinib is also a very urgent clinical need," said Dr. Wang Kai, CEO of OrigiMed.




About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the significant challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability, and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com .



About OrigiMed

OrigiMed is a medical science and technology transforming company and a partner of biopharmaceutical companies, who focuses on developing new technologies and clinical applications to help all types of cancer patients get access to precise treatment and help accelerate biomarker-driven drug development. By carrying out more comprehensive and high-throughput methods, leveraging wholesome bioinformatics analysis and clinical annotation to help match patients to approved targeted therapies, immunotherapies, and clinical trials-giving physicians and patients powerful actionable insights for navigating cancer care, ultimately aiming to fortify the evolution of cancer precision medicine. More information, please visit www.origimed.com


Company:OrigiMed

Website: www.origimed.com

Contact: Amy Huang

Telephone: 86-13052471970

Email: huangj@origimed.com


Penafian: Artikel ini diterbitkan semula dari media lain. Tujuan mencetak semula adalah untuk menyampaikan lebih banyak maklumat. Ini tidak bermakna laman web ini bersetuju dengan pandangannya dan bertanggungjawab ke atas keasliannya, dan tidak menanggung tanggungjawab undang-undang. Semua sumber di laman web ini dikumpulkan di Internet. Tujuan perkongsian adalah untuk pembelajaran dan rujukan sahaja. Sekiranya terdapat pelanggaran hak cipta atau harta intelek, sila tinggalkan mesej.
Kembali ke atas
© Hak cipta 2009-2020 Ekspres Kewangan Melayu      Hubungi kami   SiteMap